Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research




News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971
John.lezcano@informa.com
pharmaintelligence.informa.com

Can Fresh INTEREST Breathe New Life Into Faron's Traumakine?

Thu, 12/06/2018 - 5:09am

Faron's ARDS drug looked doomed after the INTEREST study earlier this year but the Finnish group claims that a DNA...

      Related Stories 

Brii Builds China Ops With Hep B Assets, New Partnerships

Thu, 12/06/2018 - 3:07am

China-focused Brii Biosciences, formed earlier this year, unveils plans to take its first projects into the clinic by way of...

      Related Stories 

India Corporate Governance Practices – Will Pharma Walk The Gandhian Path?

Wed, 12/05/2018 - 10:22pm

As Sun Pharma firefights allegations of corporate governance lapses, Scrip speaks to multiple experts on how they view the governance...

      Related Stories 

World First Korea Darbepoetin Biosimilar Approval To Speed CKD's Global Entry?

Tue, 12/04/2018 - 8:46pm

With a global first marketing authorization for its darbepoetin biosimilar in South Korea, Chong Kun Dang aims to speed up...

      Related Stories 

UPDATED: Clear 'Yes' From Shareholders On Takeda/Shire Deal

Tue, 12/04/2018 - 6:01pm

Dec. 5, 2018 was a big day in the timeline of Takeda's proposed acquisition of Shire, with shareholder votes being...

      Related Stories 

Clear 'Yes' on Shire From Takeda Shareholders

Tue, 12/04/2018 - 6:01pm

Dec. 5, 2018 was a big day in the timeline of Takeda's proposed acquisition of Shire, with shareholder votes being...

      Related Stories 

Imbruvica Replaces Chemo, Darzalex Boosts Standard Of Care In Front-Line CLL, Myeloma

Tue, 12/04/2018 - 4:25pm

Late-breaker presentations at ASH showed that replacing chemotherapy agents with Imbruvica in CLL, and adding Darzalex to Revlimid and dexamethasone...

      Related Stories 

Novartis Targets Chronic Urticaria As Ligelizumab Enters Late-Stage Trials

Tue, 12/04/2018 - 7:35am

Two Phase III studies, PEARL 1 and PEARL 2, will compare Novartis's candidate anti-IgE antibody with the previous generation anti-IgE...

      Related Stories 

Future Of Cardio And Mental Health Will Be Defined By Digital Advances

Tue, 12/04/2018 - 7:27am

Cardiovascular diseases are responsible for 30% of worldwide deaths, and about 25% of the global population experiences mental illness each...

      Related Stories 

Boehringer Bails On Biosimilars Outside US

Tue, 12/04/2018 - 6:06am

In a strategic shift confirmed by the German company, BI's Humira biosimilar Cyltezo will only be launched in the US...

      Related Stories 

Ninlaro Looking Positive In MM Maintenance On Back Of TOURMALINE Data

Mon, 12/03/2018 - 11:23pm

Takeda's Ninlaro seems to have proved its mettle in the first major placebo-controlled trial assessing a proteasome inhibitor as a...

      Related Stories 

Pages